PRETREAT · PRoteome-based assessment of vascular disease for the Establishment of a Translational REsearch plATform
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2016-01-01 → 2019-12-31
- EU contribution
- €387,000
- Participants
- 5
- Scheme
- MSCA-RISE
Lines connect the coordinator with its partners.
Results in brief
PRoteome-based assessment of vascular disease for the Establishment of a Translational REsearch plATform
Cardiovascular diseases are number one cause of death globally, with mortality rates higher than any other non-communicable disease. Vascular disease affects blood (arteries and veins) and lymph vessels of the circulatory system. Many factors, mostly associated to lifestyle (such as smoking, unhealthy diet, lack of exercise, stress etc) and/or having diabetes, being male and having high cholesterol levels favor the development of vascular disease. An active, healthy lifestyle is thus a first step towards improvement of vascular health. Specific drugs have been developed to reduce vascular disease if adherence to a healthy lifestyle is low or is without effect. These include antihypertensives (lowering blood pressure drugs); antidyslipidemics (lipid lowering drugs) and antithrombotics (anti blood clotting drugs). However these drugs can be much improved upon and that is where the PRETREAT project comes in: - PRETREAT aimed the identification of early non-invasive (blood and urine) makers of vascular disease so that intervention can be performed at a much earlier stage and hence be more effective and less aggressive (less side-effects). - PRETREAT also aimed to better understand vascular disease by studying it on the very detailed (molecular) level using modern tools such as proteomics (analysis of all proteins that are modified in disease) and thereby proposing new drug targets.
Data: CORDIS, © European Union
Project objective
Cardiovascular disease (VD) is the leading cause of mortality and morbidity in Europe and worldwide. The objective of the PRETREAT consortium is to generate a joint SME/academic European preclinical platform for providing services for detection of VD and drug development. This platform will combine the use of urinary and/or blood peptidomics in humans and in preclinical animal models of VD, together with bioinformatics and systems biology, in order to better detect, stratify and decipher the molecular mechanisms of VD, develop new animal models with high similarity to human disease, and provide new tools for obtaining information on novel drug targets.PRETREAT builds on the FP7 project Sysvasc (systems biology to identify molecular targets for vascular disease treatment, 2014-2018) and the combined expertise of the PRETREAT partners in clinical proteomics, proteomics, animal models and system medicine as the pillars to implement this platform. The work will be carried out in an extensive exchange program totaling 27 secondments. Main objectives during the secondments include establishment of the link between urinary markers and the pathophysiology of VD, identification of additional animal VD models with similarity to human VD, development of “humanized” body fluid readouts in VD models, establishment of a VD protein-centric database in order to automatically link urinary peptides to in situ changes and provide information on drug targets, and provide proof-of-concept of the utility of the proposed platform. These secondments will in parallel serve to keep information flowing within the project, increase individual research efficiency and create a multi-disciplinary working chain, train personnel, and prepare the sustainability of the results after the project. To complete training, 3 monthly webinars and four workshops are planned.
Original text from CORDIS.
Participants
Links
- View on CORDIS
- DOI: 10.3030/690966
- http://www.pretreat.eu
- https://www.ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5a79d423c&appId=PPGMS
- https://www.ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5aa94aca1&appId=PPGMS
Data: CORDIS, © European Union